Celsion Corp

NASDAQ:CLSN 3:59:55 PM EDT

3.03

+0.68 (+28.94%)

: $2.88 -0.15 (-4.95%)

Market Cap (Intraday)	100.81M
Current PE	N/A
Forward PE	N/A
2yr Forward PE	N/A

See more stats

Estimates Current Quarter

Revenue	$0.13 Million
Adjusted EPS	-$0.11

See more estimates

10-Day MA	$2.06
50-Day MA	$1.21
200-Day MA	$1.46

See more pivots

Celsion CORP Stock, NASDAQ:CLSN

997 LENOX DRIVE, SUITE 100, LAWRENCEVILLE, NJ 08648

United States of America

Phone: (609) 896-9100

Number of Employees: 29

www.celsion.com

Description

Celsion Corporation, an oncology drug development company, focuses on the development and commercialization of chemotherapeutic oncology drugs based on its proprietary heat-activated liposomal technology. The company's lead product includes ThermoDox, a liposomal encapsulation of doxorubicin that is in Phase III clinical trials for primary liver cancer; and under Phase II clinical trials for recurrent chest wall breast cancer. It has a development, product supply, and commercialization agreement with Yakult Honsha Co. Ltd. for ThermoDox; and a commercial supply agreement with Zhejiang Hisun Pharmaceutical Co. Ltd. for the production of ThermoDox in mainland China, Hong Kong, and Macau. The company also has a collaboration with the Children's Research Institute to conduct a clinical study of ThermoDox, a heat activated liposomal encapsulation of doxorubicin in combination with magnetic resonance-guided high intensity focused ultrasound to treat relapsed or refractory solid tumors in children and young adults. Celsion Corporation was founded in 1982 and is based in Lawrenceville, New Jersey.